Investor Relations
Feb 05, 2019
OPKO Health, Inc. Announces the Pricing of its Offering of Convertible Senior Notes MORE >>
Feb 04, 2019
OPKO Health, Inc. Announces Proposed Offering of Convertible Senior Notes MORE >>
Feb 01, 2019
OPKO Health Receives FDA Approval for the Point-of-Care Sangia PSA Test with the Claros® 1 Analyzer MORE >>
Jan 31, 2019
OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator MORE >>

SEC Filing Details

Document Details

Form
Filing Date
Feb 7, 2019
Document Date
Feb 4, 2019
Form Description
Report of unscheduled material events or corporate event
Filing Group
Current Reports
Company
OPKO Health, Inc.